Search
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. … [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalThis small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. … Food and Drug Administration on August 1, 2017.
Lactobacillus acidophilus
go.drugbank.com/drugs/DB15823ApprovedInvestigationalMixtures: GYNOFLOR 50 MG/0.03 MG VAJİNAL TABLET, 6 ADET, GYNOFLOR 50 MG/0.03 MG VAJİNAL TABLET, 12 ADETAcetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalAcetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
Synonyms: N-Hydroxyacetamide, N-AcetylhydroxylamineProducts: CIFLOXIN 200 MG., QUINOPRON ® INYECTABLE 200 MGAnileridine
go.drugbank.com/drugs/DB00913ApprovedIllicitWithdrawnIt is a narcotic pain reliever used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain. … Some of their side effects are also caused by actions in the CNS.
Synonyms: N-β-(p-aminophenyl)ethylnormeperidine, N-(β-(p-aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidinePirenzepine
go.drugbank.com/drugs/DB00670ApprovedWithdrawnIt promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. … An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259023] However, it could potentially be due to the short timeframe of tofersen treatment, and more longterm trials are being conducted to confirm this hypothesis.[A259023]
Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SPIsavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalAs isavuconazole displays low water solubility, it is found as an active ingredient of its prodrug, [DB06636]. … It is proposed that the intravenous and oral dosing can be used interchangeably [L1482], without the need for a repeat loading dose when transitioning from an IV to an oral formulation [A32026].
Products: CRESEMBA (100 MG HARD CAPSULES), CRESEMBA (POWDER FOR SOLUTION FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 MG/VIAL)XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalXTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. … It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
Amuvatinib
go.drugbank.com/drugs/DB12742InvestigationalAmuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. … Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma.
Synonyms: 1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro(3,2-d)pyrimidin-4-yl-, 4-[1]Benzofuro[3,2-D]Pyrimidin-4-Yl-N-(1,3-Benzodioxol-5-Ylmethyl)Piperazine-1-Carbothioamide